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Abstract
Introduction Most case series suggest that less than half of the
patients receiving a mechanical cardiac assist device as a
bridge to recovery due to severe post-cardiotomy heart failure
survive to hospital discharge. Levosimendan is the only inotropic
substance known to improve medium term survival in patients
suffering from severe heart failure.
Methods This retrospective analysis covers our single centre
experience. Between July 2000 and December 2004, 41
consecutive patients were treated for this complication. Of
these, 38 patients are included in this retrospective analysis as
3 patients died in the operating room. Levosimendan was added
to the treatment protocol for the last nine patients.
Results Of 29 patients treated without levosimendan, 20 could
be weaned off the device, 9 survived to intensive care unit
discharge, 7 left hospital alive and 3 survived 180 days. All 9
patients treated with levosimendan could be weaned, 8 were
discharged alive from ICU and hospital, and 7 lived 180 days
after surgery (p < 0.002 for 180 day survival). Plasma lactate
after explantation of the device was significantly lower (p  =
0.002), as were epinephrine doses. Time spent on renal
replacement therapy was significantly shorter (p = 0.023).
Conclusion Levosimendan seems to improve medium term
survival in patients failing to wean off cardiopulmonary bypass
and requiring cardiac assist devices as a bridge to recovery.
This retrospective analysis justifies prospective randomised
investigations of levosimendan in this group of patients.
Introduction
Failure to wean off cardiopulmonary bypass (CPB) secondary
to severe post-cardiotomy cardiac failure is a serious problem
in cardiac surgery. Adherence to clearly defined treatment
standards has been shown to be advantageous [1-3]. Phos-
phodiesterase inhibitors and catecholamines are routinely
used to treat this complication [4]. In addition to pharmaco-
therapy, circulation is supported by intraaortic balloon pump-
ing (IABP) and a trial of delayed sternal closure can be
indicated [5]. In ongoing severe cardiac failure, mechanical
assist devices are used [1-3]. Aims of therapy with these
devices are maintenance of adequate perfusion of vital organs
and a temporary reduction of cardiac work [6]; centrifugal
pumps are commonly used for this purpose. From 49% to
71% of patients are successfully weaned off these devices,
and hospital survival is quoted as ranging from 22% to 52%
[7-16]. The most commonly encountered complications are
bleeding, thrombosis, emboli, renal failure and ongoing severe
cardiac failure. Little is known about long term survival of
CABG = coronary artery bypass grafting; CPB = cardiopulmonary bypass; IABP = intraaortic balloon pumping; ICU = intensive care unit; TEE = 
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patients treated with assist devices for post-cardiotomy heart
failure [10].
Our institution, which treats, on average, 1,500 adult patients
per year undergoing CPB, introduced levosimendan for treat-
ment of this complication in February 2003. Compared with
other inotropes, levosimendan increases myocardial oxygen
consumption to a much lesser extent. There seems to be a par-
ticularly marked action on stunned myocardium [17]. The intra-
cellular concentration of calcium is not influenced by
levosimendan. The second effect of levosimendan is general
vasodilation, which leads to an increase of coronary and
splanchnic blood flow [18,19]. Levosimendan induced vasodi-
lation is achieved through opening of the ATP-dependent
potassium channels of smooth muscle cells, which is one of
the most important factors in protecting tissue from ischemia/
reperfusion injury [20]. This mechanism is also responsible for
the anti-ischemic, cardio-protective properties of levosi-
mendan [21]. Due to active metabolites, the pharmacological
effects of levosimendan are present for many days.
We conducted a retrospective review of the outcome of con-
secutive patients requiring mechanical ventricular assistance
with a centrifugal pump for post-cardiotomy heart failure
before and after we started using levosimendan for treatment
of severe post-cardiotomy heart failure.
Materials and methods
We reviewed the charts and data derived from an electronic
patient data management system (COPRA™, Leipzig, Ger-
many) of 41 consecutive adult patients undergoing implanta-
tion of a centrifugal assist device as a bridge to recovery.
Three patients died due to vasoplegia resistant to treatment
within the operating room (two conventional treated patients
and one patient in the levosimendan group); these patients
were excluded from further analysis. From 1 July 2000 to 31
December 2004, 38 patients were included in this analysis
and were observed up to 1 June 2005. We determined details
of the treatment during the intensive care unit (ICU) stay; if
patients were discharged from hospital, we contacted the
patients and if necessary their general practitioners by phone
to establish survival status.
Our bypass and anesthesia management has been described
in our standard operating procedures [22]. In short, for induc-
tion of anesthesia we used etomidate, midazolam, fentanyl and
pancuronium, and for maintenance of anesthesia fentanyl infu-
sion and isoflurane or sevoflurane were used. CPB was per-
formed using a centrifugal pump (Rotaflow™, Jostra, Hirlingen,
Germany) with a pump flow above 2.6 l·min-1·m-2 and arterial
line pressure above 60 mmHg in normothermia. Pump prime
consists of balanced electrolyte solution and hydroxyethyl
starch. All patients receive 50,000 KIU·kg-1 aprotinin at the
Figure 1
Treatment protocol of the weaning off from cardiopulmonary bypass in patients with acute or chronic impaired cardiac function Treatment protocol of the weaning off from cardiopulmonary bypass in patients with acute or chronic impaired cardiac function. IABP, intra-aortic 
balloon (contra-)pulsation; ICU, intensive care unit; MAP, mean arterial pressure; TEE, trans-esophageal echocardiography; v O2 saturation, venous 
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start of CPB. Cardioplegia is induced and maintained with
intermittent antegrade warm potassium enriched blood [23].
During CPB we maintain the hematocrit above 22% by
packed red blood cell transfusions.
During termination of CPB all patients described were moni-
tored using transesophageal echocardiography (TEE) using a
Sonos 4500 or 5500 System (Hewlett Packard, Andover,
Massachusetts, USA) and a pulmonary artery catheter with
continuous oxymetry measurement device (Opticath, Abbott,
North-Chicago, Illinois, USA). During this period we infused
vasoactive substances in every patient according to institu-
tional standards (Figure 1): norepinephrine was applied to
maintain mean arterial pressure above 60 mmHg; and in
patients with seriously impaired pump function, enoximone 0.3
to 0.5 mg·kg-1 was applied as a slow bolus injection during
cardiac reperfusion. If further inotropic support was needed
(mixed venous oxygen saturation below 60% and/or cardiac
index below 2.4 l·min-1·m-2), the patients received epinephrine
to a maximum dose of 0.15 µg·kg-1·min-1. If it was impossible
to discontinue CPB with this regime we implanted an IABP.
During a second attempt to discontinue the pump run we
increased the epinephrine dose, if required, up to 0.3 µg·kg-
1·min-1. If this attempt was unsuccessful, we proceed to
implantation of a centrifugal pump (Medtronic Biomedicus,
Minneapolis, Minnesota, USA). This pump bypassed the ven-
tricle with the worst pump function as judged by TEE and inva-
sive hemodynamic monitoring. If necessary, both ventricles
were supported. Goals of hemodynamic therapy were a mixed
venous oxygen saturation of 70% or more, and a mean arterial
pressure of 70 mmHg. Furthermore, pump flow and filling
pressures were adjusted in such a manner that slight opening
movements of the aortic valve were visible (during TEE) to
avoid intra-cardiac thrombus formation. Epinephrine infusion
was guided by the status of the supported ventricle; if possi-
ble, doses of less than 0.1 µg·kg-1·min-1 were used. First line
inotropic support was with enoximone 3 to 5 µg·kg-1·min-1,
reduced to 1 µg·kg-1·min-1 in renal failure. Heart rate was lim-
ited to 100 beats per minute using esmolol and metoprolol. In
new onset atrial fibrillation, electric cardioversion was
attempted. IABPs were triggered by the ECG and 1:1 support
was chosen. Blood component therapy was guided by coag-
ulation analysis. Heparin was used to maintain activated partial
thromboplastin time (aPTT) around 50 seconds once postop-
erative blood loss had diminished to less than 50 ml·h-1. The
access wound was closed using a plastic membrane or skin
sutures depending on the individual situation.
In February 2003, we added levosimendan to our therapy
regime as a last pharmacological option. We started applying
Figure 2
Epinephrine dosages of the intensive care unit survivors Epinephrine dosages of the intensive care unit survivors. Boxplots 
presents medians and 25 and 75 percentiles; limits are the 95 confi-
dence intervals. White boxplots are the values of the maximal epine-
phrine dosage at the day of surgery, grey boxplots are the mean 
epinephrine dosages during assist device, striped boxplots are the 
maximal epinephrine dosage during the first 24 hours after explanation 
of the assist device and black boxplots are the values of the mean 
epinephrine dosage during the first 24 hours after explantation of the 
assist device. Asterisks indicate p < 0.001 between the groups.
Table 1
Preoperative characteristics of the patients
Characteristic Conventional Levosimendan P value
n2 9 9
Age (years) 68 ± 7a 57 ± 8a 0.001
Body mass index 27.1 ± 3a 26.3 ± 3a 0.41
Male:female 19:10 8:1 0.31
LVEF 34 ± 14a 33 ± 17a 0.96
Coronary artery disease 26 7 0.55
Arterial hypertension 23 7 0.94
Pulmonary arterial hypertension 3 2 0.61
Diabetes mellitus 12 3 0.73
Chronic renal insufficiency 10 2 0.59
Peripheral vascular disease 7 2 0.94
Atrial fibrillation 12 3 0.74
Hyperlipidemia 15 4 0.42
Nicotine abuse 6 4 0.13
COPD 5 2 0.71
aMean ± standard deviation. Mann-Whitney-U test was used to 
determine p values between the groups. Chi square test was used to 
compare categorial data. COPD, chronic obstructive pulmonary 
disease; LVEF, left ventricular ejection fraction.Critical Care    Vol 10 No 1    Braun et al.
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the drug in five patients in the operating room during the
attempts to wean off CPB and, in four patients, levosimendan
therapy was started in the ICU, that is, once the assist had
been inserted. We applied an initial bolus dose of 20 µg·kg-1
over ten minutes and then continued therapy with 0.1 to 0.2
µg·kg-1·min-1 for a maximum of 48 hours because of the accu-
mulation of active metabolites [24]. Administered in this dos-
age it has been shown that the pharmacological effects of
levosimendan's active metabolites last for at least one week
after the end of application. This dosage was chosen due to
the advantageous experiences observed in the LIDO-study
[25].
The indication for explantation of the assist system was a suc-
cessful trial of clamping the device for five to ten minutes with-
out deterioration of the hemodynamic parameters. A mixed
venous saturation of 70% or more and a mean arterial pres-
sure of 65 mmHg or more had to be maintained using a dos-
age of epinephrine of 0.1 µg·kg-1·min-1 or less. In this clinical
situation every patient received a continuous infusion of enoxi-
mone.
Statistical evaluation of our retrospective data was done using
SPSS version 12.0 (IAC, Chicago, Illinois, USA). The Mann-
Whitney U test was used to make inter group comparisons. To
calculate significance in survival differences between groups
chi-square-tests were performed. Significance was assessed
at p ≤ 0.05.
Results
Demographic data and coexisting diagnoses are given in
Table 1. Surgical characteristics are given in Table 2. Survival
in relation to treatment with levosimendan is shown in Table 3.
There was no relevant difference between the two groups with
regard to treatment with enoximone. The average norepine-
phrine dosages during infusion of levosimendan were not sig-
nificantly different between patients treated with or without
levosimendan: median 0.14 µg·kg-1·min-1 (interquartile range
0.18) in the levosimendan group; and median 0.2 (interquartile
range 0.28) in the conventional treatment group. On the day
of primary surgery, the maximum dose of epinephrine was
higher in patients not receiving levosimendan. After explanta-
tion, levosimendan patients required less epinephrine (Figure
2). The median of the norepinephrine dosage after explanta-
tion was 0.06 µg·kg-1·min-1 (interquartile range 0.012) in the
levosimendan treated patients versus 0.14 µg·kg-1·min-1
(interquartile range 0.4) in the conventional treated patients (p
= 0.03).
Figure 3
Plasma lactate concentrations Plasma lactate concentrations. Boxplots presents medians and 25 and 
75 percentiles; limits are the 95 confidence intervals. White boxplots 
are the values of the maximal lactate concentrations during surgery, 
grey boxplots are the values of the maximal lactate concentrations dur-
ing assist device, and black boxplots are values of the maximal lactate 
concentrations after discharge from assist device. Asterisks indicate p 
= 0.016 between the groups.
Table 2
Surgical characteristics of the patients
Characteristic Conventional Levosimendan P value
CABG 17 6 0.84
AVR 2 1 0.79
MVR 4 1 0.71
CABG + VR 6 1 0.36
Duration of CPB (minutes) 170 ± 70a 176 ± 101a 0.65
Duration of AO (minutes) 69 ± 60a 80 ± 81a 0.76
LVAD 22 7 0.70
RVAD 5 1 0.95
BiVAD 2 1 0.86
Duration of AD (days) 3.2 ± 2a 3.8 ± 1.5a 0.20
aMean ± standard deviation. Mann-Whitney U test was used to 
calculate p-values between the groups (duration data). Chi square 
test was used to compare categorial data. AO, aortic cross 
clamping; AVR, aortic valve replacement; BiVAD, biventricular 
ventricular assist device; CABG, coronary artery bypass grafting; 
CABG + VR, CABG combination with a valve replacement; CPB, 
cardiopulmonary bypass; IABP, intra-aortic balloon pump counter-
pulsation; LVAD, left ventricular assist device; MVR, mitral valve 
replacement; RVAD, right ventricular assist device.Available online http://ccforum.com/content/10/1/R17
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After explantation of the assist device, plasma lactate concen-
trations were significantly lower in the levosimendan group
(Figure 3).
There was no significant difference in duration of mechanical
cardiac assistance with either centrifugal pumps (mean 3.4
days, range 1 to 7 days) or IABPs (mean 6.2 days, range 6 to
53 days). Mean time on mechanical ventilation was 6.2 days
(range 2 to 44 days), mean ICU stay was 27 days (range 6 to
53 days), and mean hospital stay was 60 days (range 6 to
196) without any significant difference between the groups.
The incidence of renal replacement therapy in both groups
was 80%, but there was a large difference in duration of renal
replacement therapy between the ICU survivors of the two
groups (Figure 4).
Discussion
In this retrospective observation, we were able to demonstrate
a positive effect of levosimendan on 180-day survival rates in
patients with severe post-cardiotomy heart failure. The group
of patients treated with levosimendan required less epine-
phrine in the postoperative period, showed lower plasma lac-
tate concentration after explantation of the assist device, and
significantly shorter duration of renal replacement therapy. No
difference was found between the groups regarding the inci-
dence of acute renal failure as well as ICU or hospital length
of stay.
The survival rates in the conventional treatment group were
similar to those reported by other centres; 10 studies observ-
ing the therapy with assist device implantation as a bridge to
recovery showed that weaning was possible in 49% to 71%
and discharge from hospital in 22% to 52% of patients [7-16].
In our study, 69% of the patients in the conventional therapy
group were able to be weaned from the assist device and 24%
were finally discharged from hospital. In contrast, all of the
patients in the levosimendan group were successfully weaned
and 89% could be discharged from hospital. We have taken
into consideration that the patients in the levosimendan group
were of significantly younger age than those in the conven-
tional treatment group (Table 1). The average age of the
patients in the levosimendan group was 57 years and ranged
between a minimum of 45 years and a maximum of 68 years.
This corresponds with an average age of 59 years published
in other studies.
Not many data exist on long-term survival rates of patients
receiving an assist device secondary to severe post-cardiot-
omy cardiac shock. Hoy and colleagues [10] have reported 62
cases with implanted centrifugal pumps. In that study, 27 of
the observed patients were able to be discharged from hospi-
tal, 9 died in the first year after discharge, 10 further survived
for less than 5 years, 7 survived for 6 to 10 years and 1 patient
survived for more than 10 years after the procedure.
The advantageous effects of levosimendan in patients with
acute decompensated cardiac failure have been demon-
strated in clinical trials. The multicenter RUSSLAN study [25]
investigated levosimendan in three different dosages versus
placebo in patients with acutely impaired cardiac function due
to myocardial infarction. The higher dosage of levosimendan
(bolus 24 µg·kg-1 followed by infusion of 0.4 µg·kg-1·min-1) was
associated with increased incidences of hypotension and
ischemia compared to patients who received a bolus of 24 µg
kg-1 followed by infusion of 0.2 µg × kg-1 × min-1 or patients
who received a bolus of 12 µg kg-1 followed by infusion of 0.2
µg × kg-1 × min-1 or patients who received a bolus of 6 µg kg-
1 followed by infusion of 0.1 µg × kg-1 × min-1. The total
number of levosimendan treated patients showed a signifi-
cantly reduced 14-day mortality (p = 0.031) and the 180-day
mortality tended to be lower in the levosimendan groups (p =
Figure 4
Duration of the extracorporal renal replacement Duration of the extracorporal renal replacement. Boxplots present medi-
ans and 25 and 75 percentiles; limits are the 95 confidence intervals. 
The asterisk indicates p = 0.023 between the groups.
Table 3
Survival status of the groups
Conventional Levosimendan P value
n2 9 9
AD survival 20 9 p = 0.082
ICU survival 9 8 p = 0.005
Hosp survival 7 8 p = 0.001
180-day survival 3 7 p < 0.001
Chi square test was used and p values between the groups were 
determined according to exact Fischer's test. 180-day survival, 
survival of the first 180 days after surgery; AD survival, survival of 
assist device; Hosp survival, survival of hospital stay; ICU survival, 
survival of intensive care unit stay.Critical Care    Vol 10 No 1    Braun et al.
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0.053). The multicenter LIDO study [26] investigated levosi-
mendan versus placebo in patients with acute decompen-
sated heart failure; 180-day survival was significantly improved
in the levosimendan group (p = 0.029). No controlled studies
have ever examined the effect of levosimendan administration
in cardiac surgical patients with severe impairment of ventricu-
lar function. Lehmann and co-workers [27] reported 10
patients with severe cardiogenic shock undergoing emer-
gency coronary artery bypass grafting (CABG). These
patients were treated with levosimendan. Two patients died
and eight patients showed an excellent clinical outcome with-
out further complications. One study showed a significant
improvement of hemodynamic measurements in patients
undergoing CABG surgery with normal ventricular function
[18].
Morelli and co-workers showed that levosimendan improved
the left ventricular stroke work index in septic patients with
reduced ventricular function compared to patients treated with
dobutamine [19]. The authors observed no difference in nore-
pinephrine dosages between the groups. Their patients were
treated with optimal fluid loading. In our retrospective analysis,
we also found no increase in administered norepinephrine
dosages in levosimendan treated patients. In Morelli's study,
levosimendan led to an increase in gastric mucosal blood flow,
creatinine clearance, and urinary output. The authors found
decreased troponin and lactate concentrations in levosi-
mendan treated patients. In our retrospective observation, the
duration of renal replacement therapy was significantly lower
in the levosimendan group compared to the conventional ther-
apy group. This could be due to improved renal perfusion.
The significantly lower plasma lactate concentration following
device explantation in levosimendan treated patients could
possibly be an indicator for improved splanchnic perfusion and
for protection of organs from ischemia/reperfusion injury
through opening of ATP-dependent potassium channels by
levosimendan. Another explanation for this finding could be a
reduced administration of epinephrine in the levosimendan
group. Epinephrine itself may lead to impaired splanchnic per-
fusion and metabolic alterations resulting in hyperlactatemia
[28].
Conclusion
The 180-day survival rate in patients receiving an assist device
due to severe post-cardiotomy cardiac failure was significantly
improved by treatment with levosimendan. A significant reduc-
tion of the epinephrine dose was possible. The incidence of
hyperlactatemia was lower and the duration of renal replace-
ment therapy was shorter.
The results presented here must be interpreted cautiously
since this observation is retrospective. Our data justify future
prospective randomised trials of levosimendan in cardiac sur-
gical patients suffering from severe heart failure.
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